$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Cellular HIV-1 Immune Responses in Natural Infection and After Genetic Immunization

Scandinavian journal of infectious diseases, v.33 no.2, 2001년, pp.83 - 96  

Calarota, Sandra A. ,  Wahren, Britta

Abstract

By eliminating infected cells, virus-specific cytotoxic T-lymphocytes (CTL) play a central role in host protection. Many studies to date seem to support the concept that human immunodeficiency virus (HIV)-specific CTL responses contribute to the control of viral replication, and thus delay the onset of disease. The feasibility of improving the virus-specific T-cell immunity by immunizing during the asymptomatic phase of infection has been studied in man. DNA vaccination is a novel strategy, involving direct inoculation of genetic material that is capable of producing antigen intracellularly for presentation to CTL. Such DNA-based immunization has been shown in animal models to be effective for the induction of both cellular and humoral immune responses as well as for protection from infectious challenge. This article reviews the cell-mediated immune responses in natural HIV-1 infection and the induction by DNA vaccination in humans.

참고문헌 (163)

  1. Virus-specific CD8 + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol Borrow P 6103 68 1994 

  2. J Virol Koup RA 4650 68 1994 10.1128/JVI.68.7.4650-4655.1994 

    상세보기 crossref

  3. CD8 + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci USA Mackewicz CE 2308 92 1995 

  4. J Infect Dis Toso JF 964 172 1995 10.1093/infdis/172.4.964 

    상세보기 crossref

  5. J Exp Med Klein MR 1365 181 1995 10.1084/jem.181.4.1365 

    상세보기 crossref

  6. J Virol Rinaldo C 5838 69 1995 10.1128/JVI.69.9.5838-5842.1995 

    상세보기 crossref

  7. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol van Baalen CA 1913 78 1997 

  8. Immunol Lett Rowland-Jones SL 9 66 1999 10.1016/S0165-2478(98)00179-5 

    상세보기 crossref

  9. Nat Med Koenig S 330 1 1995 10.1038/nm0495-330 

    상세보기 crossref

  10. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med Riddell SR 216 2 1996 

  11. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood Lieberman J 2196 90 1997 

  12. Nat Med Brodie SJ 34 5 1999 10.1038/4716 

    상세보기 crossref

  13. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood Tan R 1506 93 1999 

  14. Curr Opin Chem Biol Wahren B 183 1 1997 10.1016/S1367-5931(97)80008-7 

    상세보기 crossref

  15. Weiner DB. Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J Chattergoon M 753 11 1997 

  16. Proc Natl Acad Sci USA Wang B 4156 90 1993 10.1073/pnas.90.9.4156 

    상세보기 crossref

  17. AIDS Res Hum Retroviruses Fuller DH 1433 10 1994 10.1089/aid.1994.10.1433 

    상세보기 crossref

  18. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol Yasutomi Y 678 70 1996 

  19. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet Calarota S 1320 351 1998 

  20. J Immunol Calarota SA 2330 163 1999 10.4049/jimmunol.163.4.2330 

    상세보기 crossref

  21. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis MacGregor RR 92 178 1998 

  22. Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Clin Immunol Boyer JD 100 90 1999 

  23. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science Wang R 476 282 1998 

  24. Eur J Immunol Kägi D 3256 25 1995 10.1002/eji.1830251209 

    상세보기 crossref

  25. Walker, Bruce D., Chakrabarti, Sekhar, Moss, Bernard, Paradis, Timothy J., Flynn, Theresa, Durno, Amy G., Blumberg, Richard S., Kaplan, Joan C., Hirsch, Martin S., Schooley, Robert T.. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature, vol.328, no.6128, 345-348.

    상세보기 crossref

  26. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature Plata F 348 328 1987 

  27. AIDS Walker BD 177 4 1990 10.1097/00002030-199003000-00001 

    상세보기 crossref

  28. J Immunol Hoffenbach A 452 142 1989 10.4049/jimmunol.142.2.452 

    상세보기 crossref

  29. Carboxyl-terminal and central regions of human immunodeficiency virus-1 nef recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis. J Clin Invest Hadida F 53 89 1992 

  30. Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex. J Immunol Jassoy C 3113 149 1992 

  31. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell Cheynier R 373 78 1994 

  32. J Exp Med Musey L 293 185 1997 10.1084/jem.185.2.293 

    상세보기 crossref

  33. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8 + lymphocyte activity. J Infect Dis Ferbas J 329 172 1995 

  34. AIDS McMichael AJ S155 8 1 1994 

  35. AIDS Lamhamedi-Cherradi S 421 9 1995 10.1097/00002030-199509050-00002 

    상세보기 crossref

  36. Buseyne F. Cytotoxic T lymphocytes in human immunodeficiency virus infection: regulator genes. Curr Top Microbiol Immunol Riviere Y 65 189 1994 10.1007/978-3-642-78530-6_4 

    crossref

  37. J Virol Littaua RA 608 66 1992 10.1128/JVI.66.1.608-611.1992 

    상세보기 crossref

  38. Human CD4 + cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J Infect Dis Stanhope PE 92 168 1993 

  39. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantification of effector cell populations with p17 and p24 specificities. J Exp Med Koup RA 1593 174 1991 

  40. AIDS Lamhamedi-Cherradi S 1249 6 1992 10.1097/00002030-199211000-00002 

    상세보기 crossref

  41. J Exp Med Caramichael A 249 177 1993 10.1084/jem.177.2.249 

    상세보기 crossref

  42. Human immunodeficiency virus type 1 (HIV-1)- and Epstein-Barr virus-specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1-infected persons. J Infect Dis Geretti AM 34 174 1996 

  43. Science Walker CM 1563 234 1986 10.1126/science.2431484 

    상세보기 crossref

  44. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8 + T cells. Immunol Today Levy JA 217 17 1996 

  45. J Infect Dis Barker E S485 179 3 1999 10.1086/314808 

    상세보기 crossref

  46. Identification of RANTES, MIP-1α, and MIP- 1β as the major HIV-suppressive factors produced by CD8 + T cells. Science Cocchi F 1811 270 1995 

  47. Lancet Mackewicz CE 1671 344 1994 10.1016/S0140-6736(94)90459-6 

    상세보기 crossref

  48. Evolution and plasticity of CTL responses against HIV. Curr Opin Immunol Autran B 546 8 1996 

  49. An activated CD8 + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol Landay AL 106 69 1993 

  50. J Immunol Luzuriaga K 433 154 1995 10.4049/jimmunol.154.1.433 

    상세보기 crossref

  51. Adv Immunol Rowland-Jones S 277 65 1997 10.1016/S0065-2776(08)60745-2 

    상세보기 crossref

  52. Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8 + T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies. AIDS van Baalen CA 781 7 1993 

  53. A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res Hum Retroviruses Lubaki MN 1427 10 1994 

  54. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol Spector DH 2298 64 1990 

  55. Science Lusso P 848 247 1990 10.1126/science.2305256 

    상세보기 crossref

  56. Proc Natl Acad Sci USA Andäng M 12749 96 1999 10.1073/pnas.96.22.12749 

    상세보기 crossref

  57. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science Altman J 94 274 1996 

  58. J Exp Med Lalvani A 859 186 1997 10.1084/jem.186.6.859 

    상세보기 crossref

  59. Immunity Murali-Krishna K 177 8 1998 10.1016/S1074-7613(00)80470-7 

    상세보기 crossref

  60. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods Suni MA 89 212 1998 

  61. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS Larsson M 767 13 1999 

  62. Curr Opin Immunol Rowland-Jones SL 448 7 1995 10.1016/0952-7915(95)80087-5 

    상세보기 crossref

  63. Shearer, Gene M., Clerici, Mario. Protective immunity against HIV infection: has nature done the experiment for us?. Immunology today, vol.17, no.1, 21-24.

    상세보기 crossref

  64. Immunol Today Heeney JL 247 20 1999 10.1016/S0167-5699(98)01437-6 

    상세보기 crossref

  65. J Infect Dis Bernard NF 538 179 1999 10.1086/314621 

    상세보기 crossref

  66. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis Goh WC 548 179 1999 

  67. Curr Opin Immunol Franco A 524 7 1995 10.1016/0952-7915(95)80098-0 

    상세보기 crossref

  68. Effects of HIV-1 Tat on expression of HLA class I molecules. J Acquir Immune Defic Syndr Hum Retrovirol Matsui M 233 11 1996 10.1097/00042560-199603010-00003 

    상세보기 crossref

  69. Nat Med Schwartz O 338 2 1996 10.1038/nm0396-338 

    상세보기 crossref

  70. J Exp Med Koup RA 779 180 1994 10.1084/jem.180.3.779 

    상세보기 crossref

  71. Cell McMichael A 673 93 1998 10.1016/S0092-8674(00)81428-2 

    상세보기 crossref

  72. J Exp Med Couillin I 1129 180 1994 10.1084/jem.180.3.1129 

    상세보기 crossref

  73. Klenerman, Paul, Rowland-Jones, Sarah, McAdam, Steve, Edwards, Jon, Daenke, Susan, Lalloo, David, Köppe, Britta, Rosenberg, William, Boyd, Diana, Edwards, Anne, Giangrande, Paul, Phillips, Rodney E., McMichael, Andrew J.. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature, vol.369, no.6479, 403-407.

    상세보기 crossref

  74. Science Meier U-C 1360 270 1995 10.1126/science.270.5240.1360 

    상세보기 crossref

  75. Immunol Today Klein MR 317 19 1998 10.1016/S0167-5699(98)01288-2 

    상세보기 crossref

  76. N Engl J Med Wahren B 393 315 1986 

  77. Shearer, Gene M., Clerici, Mario. Early T-helper cell defects in HIV infection :. AIDS, vol.5, no.3, 245-254.

    상세보기 crossref

  78. J Virol Wahren B 2017 61 1987 10.1128/JVI.61.6.2017-2023.1987 

    상세보기 crossref

  79. HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. Clin Exp Immunol Pontesilli O 419 100 1995 

  80. AIDS Res Hum Retroviruses Rosenberg ES S143 14 1998 

  81. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med Redfield RR 1677 324 1991 

  82. J Acquir Immune Defic Syndr Hum Retrovirol Kundu SK 26974 15 1997 10.1097/00042560-199708010-00004 

    상세보기 crossref

  83. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr Wahren B 220 7 1994 

  84. AIDS Leandersson A-C 157 12 1998 10.1097/00002030-199802000-00005 

    상세보기 crossref

  85. Lancet Sandström E 1735 353 1999 10.1016/S0140-6736(98)06493-9 

    상세보기 crossref

  86. J Infect Dis Ratto-Kim S 337 179 1999 10.1086/314587 

    상세보기 crossref

  87. Immunol Today Tighe H 89 19 1998 10.1016/S0167-5699(97)01201-2 

    상세보기 crossref

  88. Proc Natl Acad Sci USA Fynan EF 11478 90 1993 10.1073/pnas.90.24.11478 

    상세보기 crossref

  89. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science Ulmer JB 1745 259 1993 

  90. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med Boyer JD 526 3 1997 

  91. Genetic immunization is a simple method for eliciting an immune response. Nature Tang D 152 356 1992 

  92. Influenza virus nucleoprotein-specific immunoglubulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol Pertmer TM 6119 70 1996 

  93. J Immunol Feltquate DM 2278 158 1997 10.4049/jimmunol.158.5.2278 

    상세보기 crossref

  94. Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand J Immunol Asakura Y 326 46 1997 

  95. Springer Semin Immunopathol Corr M 139 19 1997 10.1007/BF00870264 

    상세보기 crossref

  96. Vaccine Robinson HL 785 15 1997 10.1016/S0264-410X(96)00249-6 

    상세보기 crossref

  97. Mol Med Fu T-M 362 3 1997 10.1007/BF03401683 

    상세보기 crossref

  98. Adv Exp Med Biol Liu MA 187 452 1998 10.1007/978-1-4615-5355-7_21 

    crossref

  99. J Immunol Corr M 4721 163 1999 10.4049/jimmunol.163.9.4721 

    상세보기 crossref

  100. Immune responses to the HIV rev regulatory gene. Antibiot Chemother Wahren B 105 48 1996 

  101. Theoretical Biology and Biophysics Group. Los Alamos Korber BTM 1998 

  102. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophagetropic and T-lymphotropic HIV-1 strains. J Virol Huang L 8952 72 1998 

  103. Mol Cell Biol Kalland K-H 7436 14 1994 10.1128/MCB.14.11.7436 

    상세보기 crossref

  104. Nat Med Miller RH 389 3 1997 10.1038/nm0497-389 

    상세보기 crossref

  105. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J Gen Virol Braun R 2965 79 1998 

  106. Biogenic Amines Kjerrström A 93 15 1999 

    상세보기

  107. Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine Hinkula J 874 15 1997 

  108. Proc Natl Acad Sci USA McClements WL 11414 93 1996 10.1073/pnas.93.21.11414 

    상세보기 crossref

  109. J Virol Robert-Guroff M 3391 64 1990 10.1128/JVI.64.7.3391-3398.1990 

    상세보기 crossref

  110. Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J Virol Shugars D 4639 67 1993 

  111. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. AIDS Kelleher AD 175 12 1998 

  112. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science Autran B 112 277 1997 

  113. Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet Li TS 1682 351 1998 

  114. Quantification of HIV-1-specific cytotoxic T lymphocytes and plasma viral load of viral RNA. Science Ogg GS 2103 279 1998 

  115. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol Ogg GS 797 73 1999 

  116. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis Dalod M 61 178 1998 

  117. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis Markowitz M 525 179 1999 

  118. J Infect Dis Malhotra U 121 181 2000 10.1086/315202 

    상세보기 crossref

  119. Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect Kaufmann GR 218 75 1999 

  120. Immunol Lett Pontesilli O 213 66 1999 10.1016/S0165-2478(98)00160-6 

    상세보기 crossref

  121. J Infect Dis Pontesilli O 76 180 1999 10.1086/314837 

    상세보기 crossref

  122. Nature Krieg AM 546 374 1995 10.1038/374546a0 

    상세보기 crossref

  123. CpG motifs as immune adjuvants. Vaccine Klinman DM 19 17 1999 

  124. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science Sato Y 352 273 1996 

  125. Nat Med Roman M 849 3 1997 10.1038/nm0897-849 

    상세보기 crossref

  126. Ann N Y Acad Sci Nichols WW 30 772 1995 10.1111/j.1749-6632.1995.tb44729.x 

    상세보기 crossref

  127. Hum Gene Ther Martin T 759 10 1999 10.1089/10430349950018517 

    상세보기 crossref

  128. J Immunol Ertl HCJ 3579 156 1996 10.4049/jimmunol.156.10.3579 

    상세보기 crossref

  129. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I Env/Rev vaccine in HIV-infected recipients: follow-up data. J Infect Dis MacGregor RR 181: 406 2000 

  130. Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Lancet Livingstone WJ 649 348 1996 

  131. J Immunol Joly P 2193 143 1989 10.4049/jimmunol.143.7.2193 

    상세보기 crossref

  132. Eur J Immunol Sadat-Sowti B 737 21 1991 10.1002/eji.1830210329 

    상세보기 crossref

  133. Curr Opin Immunol Cross-clade Gotch F. 388 10 1998 10.1016/S0952-7915(98)80109-X 

    상세보기 crossref

  134. J Infect Dis El-Daher N 306 168 1993 10.1093/infdis/168.2.306 

    상세보기 crossref

  135. J Acquir Immune Defic Syndr Hum Retrovirol Perales M-A 27 10 1995 

  136. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis Corey L 301 177 1998 

  137. J Infect Dis Fleury B 734 174 1996 10.1093/infdis/174.4.734 

    상세보기 crossref

  138. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS Belshe RB 2407 12 1998 

  139. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis Wright PF 1230 177 1998 

  140. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8 + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis Fast P 290 180 1999 

  141. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J Immunol Shearer GM 2514 137 1986 

  142. Immunol Today Clerici M 107 14 1993 10.1016/0167-5699(93)90208-3 

    상세보기 crossref

  143. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA Clerici M 42 271 1994 

  144. Immunology Mathiesen T 453 67 1989 

    상세보기

  145. HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J Acquir Immune Defic Syndr Wahren B 448 2 1989 

  146. Cellular and humoral antigenic epitopes in HIV and SIV. Immunology Nixon DF 515 76 1992 

  147. Chem Immunol Siliciano RF 127 56 1993 10.1159/000421952 

    상세보기 crossref

  148. A dose-ranging study of a prototype synthetic HIV-1 MN V3 branched peptide vaccine. J Infect Dis Gorse GJ 330 173 1996 

  149. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis Belshe RB 1387 168 1993 

  150. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann Intern Med Graham BS 270 125 1996 

  151. HIV-1 MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1 MN recombinant glycoprotein 120 vaccine. AIDS Res Hum Retroviruses Gorse GJ 115 15 1999 

  152. AIDS Res Hum Retroviruses Pialoux G 373 11 1995 10.1089/aid.1995.11.373 

    상세보기 crossref

  153. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis Graham BS 244 166 1992 

  154. Presence at different clinical stages. J Immunol Ljunggren K 2263 139 1987 

  155. Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses Tyler DS 557 5 1989 10.1089/aid.1989.5.557 

    상세보기 crossref

  156. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol Koup RA 215 4 1991 

  157. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol Tyler DS 3375 144 1990 

  158. Analyses of functional antibody responses in HIV-1-infected individuals after vaccination with rgp160. Clin Diagn Virol Broliden K 115 6 1996 

  159. J Virol Yang OO 5799 70 1996 10.1128/JVI.70.9.5799-5806.1996 

    상세보기 crossref

  160. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens. J Virol Jassoy C 2844 67 1993 

  161. Cytotoxic CD8 + T lymphocytes reactive with human immunodeficiency virus-1 produce granulocyte/macrophage colony-stimulating factor and variable amounts of interleukins 2, 3, and 4 following stimulation with the cognate epitope. Clin Immunol Immunopathol Price P 100 74 1995 

  162. Immunol Today Zinkernagel RM 262 15 1994 10.1016/0167-5699(94)90005-1 

    상세보기 crossref

  163. Induction of HIV-1 replication in a chronically infected T-cell line by cytotoxic T lymphocytes. J Acquir Immune Defic Syndr Harrer T 865 6 1993 

섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로